Daniel Baker
Analyst · Cowen. Your line is open
01:20 Also on today's call is our Vice President of Advanced Technology, Pete Eames. We’ll hear from Pete in a few minutes. Since Joe is new, I'll present the financials as well as the business review today, Pete will cover new products and R&D, and then we'll open the call to questions. Comments we may make that relate to future plans, events, financial results or performance, are forward-looking statements that are subject to certain risks and uncertainties, including, among others, such factors as risks and uncertainties related to future sales and revenue, uncertainties related to future stock repurchases and dividend payments, our dependence on critical suppliers and packaging vendors, risks related to renewals of agreements with certain customers and risks related to the COVID-19 pandemic as well as the risk factors listed from time to time in our filings with the SEC, including our annual report on Form 10-K for the year ended March 31, 2021, as updated in subsequent filings. 02:19 Links to the documents we filed this afternoon are available through the SEC's website, our website and our Twitter timeline. Actual results could differ materially from the information provided, and we undertake no obligation to update forward-looking statements we may make. 02:36 We're pleased to report solid earnings despite supply chain disruptions that delayed product shipments. More importantly, we ended the quarter well positioned with work in process product inventories. 02:50 I'll cover some details of the financials. Total revenue for the most recent quarter decreased 4% to $6.29 million from $6.53 million in the prior-year quarter. The decrease was due to a 7% decrease in product sales, partially offset by an 86% increase in contract R&D. Net income for the third quarter of fiscal 2022 decreased 12% to $3.47 million, or $0.72 per diluted share, compared to $3.93 million, or $0.81 for the prior-year quarter. 03:29 We believe the impact of the COVID-19 pandemic and customer demand was significantly less in the quarter and nine months ended December 31, 2021, compared to the prior year periods. We believe the impact on – of the pandemic on our supply chain, however, was significantly more in the most recent quarter and nine months than in the prior year periods. 03:56 Gross profit margin decreased to 78% in the third quarter of fiscal 2022 from 84% in the third quarter of fiscal 2021, primarily due to product mix and increased product costs. Like most companies in the semiconductor industry, many of our cost increase, including foundry wafers, chemicals, packaging costs and labor. 04:23 In response to increased costs, we canceled some discounts and increased some prices in the past quarter. More price increases became effective at the start of the calendar year. In the past quarter, we quoted 16-week lead times on most of our parts. Therefore, if we hit our goals, of course, many of the parts where we quoted 16 weeks will be shipped this quarter. 16-week lead times are much longer than before the pandemic or even a few months ago. But according to the most recent monthly market update by one of our distributors, the lead time for parts from one of our traditional semiconductor competitors is 52 to 80 weeks or above. 05:07 Expenses for the quarter decreased 14% from the prior year due to a 15% decrease in R&D and a 13% decrease in SG&A. The decrease in R&D expense was primarily due to staffing changes and the completion of certain product development activities. The decrease in SG&A was primarily due to staffing changes. 5:32 Interest income for the third quarter of fiscal 2022 decreased 22% due a decrease in our available for sale securities and a decrease in the average interest rates on those securities. Net income for the quarter was $3.47 million or $0.72 per diluted share compared to $3.93 million or $0.81 last year. 05:56 We continue to generate strong profitability. Operating margin was 64%, pre-tax margin was 69% and net margin was 55%. For the first nine months of fiscal 2022, total revenue increased 31% to $20.3 million from $15.5 million in the prior year. Product sales increased 31% and contract R&D increased 17%. 6:26 Net income for the first nine months increased 25% from the prior year period to $10.7 million or $2.21 per diluted share, from $8.56 million, or $1.77 per share, for the first nine months of fiscal 2021. 06:47 Capital expenditures were $58,000 in the first nine months of the fiscal year. We expect that number to increase significantly this quarter, the fourth quarter since we plan to deploy several new test handlers to increase our production test capacity and alleviate potential bottlenecks. We repurpose part of the building to make room for the new equipment. 07:11 We paid $1 per share dividend in the past quarter and today, we announced that our Board of Directors declared another quarterly dividend of $1 per share payable February 28th to shareholders of record as of January 31. 07:27 Turning to the past quarter's business highlights. Some analysts have said global semiconductor shortages could last several more years. That would pose both medium-term opportunities and threats. We took advantage of some of the opportunities by winning business because we have shorter lead times than traditional semiconductors, and we can keep that business by demonstrating we’re a reliable supplier with excellent product performance in quality. 07:55 We've addressed the threats posed by the shortages by increasing work in process inventory. We are investing in additional production and test equipment. We expanded our production space. We have invested in tooling and materials for alternate packaging vendors, and we have invested in tooling for onshore foundry wafers. With these steps, as I discussed in the financial review, although lead times are longer than they have been, they are much better than industry averages. 08:27 We're proud to supply products to some of the world's most demanding customers, including Abbott's Pacesetter subsidiary. Abbott as a leading supplier of implantable medical devices. I'm pleased to report that we have reached a tentative agreement to extend our supplier partnering contract with Abbott. The extension will run through the end of 2022 and will include a price increase in the face of our increased materials and manufacturing costs. 08:58 We'll follow the amendment on our current report on Form 8-K after it's fully executed. There's still some in-person trade shows and conferences. Our Taiwan Distributor Caltech International exhibited Taipei International Industrial Automation exhibition in December. Caltech reported turnout was lighter than before the pandemic, but they still had some leads. 09:24 The joint MMM Intermag Conference, a major conference for magnetic since spintronics was last week. Highlights of our participation are on our website and Twitter timeline. We provided several types of our giant Magnetoresistance and Tunneling Magnetoresistance sensors to student entrance at the conference so they could learn how to use them. 09:47 The students came up with some corporate applications including a magnetic flute and a beer level sensor. There links to videos on our Twitter timeline. Now, I'd like to turn the call over to Peter Eames, our Vice President of Advanced Technology to cover new products and product development. 10:06 Pete has been on these calls before, he's been within the, since 2003 and he has been in this current position since 2017. Pete has a PhD in experimental condensed matter physics from the University of Minnesota. Pete?